💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Zuranolone

CHEMBL4105630 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
409.6 g/mol
LogP
4.5
Phase
4

Zuranolone is a neuroactive steroid and positive allosteric modulator of GABA-A receptors that binds to synaptic and extrasynaptic GABA-A receptor complexes, enhancing chloride ion conductance and overall inhibitory neurotransmission to reduce neuronal hyperexcitability associated with mood disorders. It is approved as a two-week oral treatment course for major depressive disorder and postpartum depression, offering rapid onset of antidepressant effects. Unlike SSRIs, it targets GABAergic rather than monoaminergic pathways, potentially addressing neurobiological underpinnings of depression related to GABA deficiency.

Molekularmasse

409,6000 g/mol

LogP

4,50

TPSA

78,90 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Bipolar Disorder Insomnia Stroke Major Depressive Disorder

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@@]1(O)CC[C@H]2[C@H](CC[C@@H]3[C@@H]2CC[C@]2(C)[C@@H](C(=O)Cn4cc(C#N)cn4)CC[C@@H]32)C1

                

                

                
                

                    
InChI

                    
InChI=1S/C25H35N3O2/c1-24(30)9-7-18-17(11-24)3-4-20-19(18)8-10-25(2)21(20)5-6-22(25)23(29)15-28-14-16(12-26)13-27-28/h13-14,17-22,30H,3-11,15H2,1-2H3/t17-,18+,19-,20-,21+,22-,24-,25+/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C25H35N3O2

                    

                    
                    

                        
HBD / HBA

                        
1 / 4

                    

                    
                    

                        
Rotierbare Bindungen

                        
3

                    

                    
                    
                    

                        
Schwere Atome

                        
30

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
Zuranolone is a neuroactive steroid and positive allosteric modulator of GABA-A receptors that binds to synaptic and extrasynaptic GABA-A receptor complexes, enhancing chloride ion conductance and overall inhibitory neurotransmission to reduce neuronal hyperexcitability associated with mood disorders. It is approved as a two-week oral treatment course for major depressive disorder and postpartum depression, offering rapid onset of antidepressant effects. Unlike SSRIs, it targets GABAergic rather than monoaminergic pathways, potentially addressing neurobiological underpinnings of depression related to GABA deficiency.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Zuranolone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL4105630.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 86294073.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.